{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:42:12Z","timestamp":1771720932914,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Merck & Company, Incorporated","award":["56367"],"award-info":[{"award-number":["56367"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Carbapenem-resistant Enterobacteriaceae (CRE) cause significant mortality and are resistant to most antimicrobial agents. Imipenem\/relebactam, a novel beta-lactam\/beta-lactamase inhibitor combination, and 16 other antimicrobials were evaluated against non-metallo-beta-lactamase-producing carbapenem-resistant Enterobacteriaceae clinical isolates from a United States tertiary academic medical center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate imipenem\/relebactam and other commonly utilised antimicrobial agents against carbapenem-resistant Enterobacteriaceae. Methods: Clinical isolates (n\u00a0\u00a0=\u00a096) resistant to ertapenem or meropenem by BD Phoenix (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and negative for metallo-beta-lactamase-production by an EDTA (Sigma-Aldrich Corp., St. Louis, MO, USA)\/phenylboronic acid (Sigma-Aldrich Corp., St. Louis, MO, USA) disk diffusion assay were identified and collected from January 2012 to January 2017. In vitro susceptibility by broth microdilution was performed according to CLSI guidelines using CLSI susceptibility breakpoints for 17 antimicrobials (Sigma-Aldrich Corp., St. Louis, MO, USA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CRE primarily produced Klebsiella pneumoniae carbapenemase (KPC) and consisted primarily of K. pneumoniae (55%) and Enterobacter spp. (25%), followed by Citrobacter spp. (10%), Escherichia coli (5%), and others (5%). CRE were most susceptible to imipenem\/relebactam (100%), followed by amikacin (85%), tigecycline (82%), and polymyxin B\/colistin (65%). The median reduction of imipenem minimum inhibitory concentrations (MICs) of non-MBL-producing CRE was 16-fold but ranged from 0.5 to\u00a0&amp;gt;512-fold. The MIC50, MIC90 and MIC range of imipenem\/relebactam was 0.5\/4, 1\/4 and 0.06\/4\u20131\/4 mg\/L, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Imipenem\/relebactam exhibits excellent activity against CRE that produce KPC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/femspd\/ftz040","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T18:47:51Z","timestamp":1565203671000},"source":"Crossref","is-referenced-by-count":17,"title":["Imipenem\/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant <i>Enterobacteriaceae<\/i> from an academic medical center"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-9096","authenticated-orcid":false,"given":"Brandon","family":"Kulengowski","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington 40536, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S","family":"Burgess","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington 40536, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"key":"2021052203593023600_bib1","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"2021052203593023600_bib2","volume-title":"Tracking CRE. Centers for Disease Control and Prevention","author":"Centers for Disease Control and Prevention"},{"key":"2021052203593023600_bib3","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - Ninth Edition","author":"CLSI","year":"2012"},{"key":"2021052203593023600_bib4","volume-title":"Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline \u2013 Fourth Edition","author":"CLSI","year":"2014"},{"key":"2021052203593023600_bib5","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard \u2013 Tenth Edition","author":"CLSI","year":"2015"},{"key":"2021052203593023600_bib6","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Eighth Informational Supplement","author":"CLSI","year":"2018"},{"key":"2021052203593023600_bib7","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.01222-13","article-title":"Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence","volume":"58","author":"Falagas","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052203593023600_bib8","doi-asserted-by":"crossref","first-page":"pii: e00642","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052203593023600_bib9","doi-asserted-by":"crossref","first-page":"pii: e00169","DOI":"10.1128\/AAC.00169-18","article-title":"In vitro activity of imipenem-relebactam against clinical isolates of gram-negative bacilli isolated in hospital laboratories in the United States - SMART 2016","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052203593023600_bib10","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1128\/JCM.02129-13","article-title":"Irreproducible and uninterpretable Polymyxin B MICs for Enterobacter cloacae and Enterobacter aerogenes","volume":"51","author":"Landman","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2021052203593023600_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"2021052203593023600_bib12","doi-asserted-by":"crossref","first-page":"pii: e00174","DOI":"10.1128\/AAC.00174-18","article-title":"Relebactam is a potent inhibitor of the KPC-2 beta-lactamase and restores the susceptibility of imipenem against KPC-producing Enterobacteriaceae","volume":"62","author":"Papp-Wallace","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052203593023600_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021052203593023600_bib14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1517\/14656566.2016.1145658","article-title":"Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply \u201cprecision medicine\u201d to antimicrobial chemotherapy?","volume":"17","author":"Perez","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"2021052203593023600_bib15","volume-title":"Clinical outcomes of infections caused by KPC-producing organisms","author":"Phillips","year":"2009"},{"key":"2021052203593023600_bib16","doi-asserted-by":"crossref","first-page":"pii: e00533","DOI":"10.1128\/AAC.00533-18","article-title":"In vitro activity of imipenem-relebactam and ceftolozane-tazobactam against resistant gram-negative bacilli","volume":"62","author":"Schmidt-Malan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052203593023600_bib17","first-page":"pii: e02097","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021052203593023600_bib18","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/jac\/dkq210","article-title":"A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates","volume":"65","author":"Tsakris","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2021052203593023600_bib19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QCO.0000000000000493","article-title":"Optimizing therapy in CRE infections","volume":"31","author":"Tumbarello","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2021052203593023600_bib20","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2021052203593023600_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infectious diseases and therapy"},{"key":"2021052203593023600_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"}],"container-title":["Pathogens and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/femspd\/advance-article-pdf\/doi\/10.1093\/femspd\/ftz040\/29024909\/ftz040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/femspd\/article-pdf\/77\/4\/ftz040\/38097437\/ftz040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/femspd\/article-pdf\/77\/4\/ftz040\/38097437\/ftz040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T04:01:52Z","timestamp":1621656112000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/femspd\/article\/doi\/10.1093\/femspd\/ftz040\/5542198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/femspd\/ftz040","relation":{},"ISSN":["2049-632X"],"issn-type":[{"value":"2049-632X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,6,1]]},"article-number":"ftz040"}}